Promising drug trial for rare pancreatic cancer stopped early
NCT ID NCT06158516
First seen Jun 11, 2026 · Last updated Jun 16, 2026 · Updated 1 time
Summary
This study tested whether the drug surufatinib could help prevent pancreatic neuroendocrine tumors from coming back after surgery. The trial was planned for many participants but was stopped early with only 6 people enrolled. Because it ended early, we don't have clear answers on whether the drug works better than a placebo.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC NEUROENDOCRINE TUMOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Changhai Hospital
Shanghai, 200433, China
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.